Jubilant Ingrevia CDMO push: FY30 EBITDA target ₹2,000 Cr

Growth is shifting toward higher-value segments

Jubilant Ingrevia’s recent commentary and disclosures point to a clear change in where incremental growth is expected to come from. The company is pushing more of its portfolio and capital toward specialty chemicals, CDMO, and human-grade nutrition. Management has positioned this mix upgrade as central to margin improvement, supported by cost savings and operating leverage. At the same time, it has acknowledged that the market is looking for sustained proof of the margin profile through cycles.

The pivot is being backed by capital expenditure that is moving closer to monetisation. Nearly ₹2,000 crore of capex is described as approaching monetisation and directed at higher-value outputs. The business mix is upgrading toward CDMO, fine chemicals, and human-grade vitamin B3, where margins are described as structurally better.

Specialty Chemicals emerges as the new growth engine

Within the company’s disclosures, Specialty Chemicals, which includes Fine Chemicals and CDMO, is repeatedly highlighted as the key driver. Specialty Chemicals recorded 12% revenue growth and maintained margins of 26%, supported by strong Fine Chemicals and CDMO sales. The segment is also described as consistently delivering robust EBITDA margins in the 24–26% range.

Management has framed this change as a structural shift away from commoditised products. CEO and Managing Director Deepak Jain said the company has moved from being commodity-heavy to specialty-focused, noting that specialty chemicals and nutrition together contribute 90% of EBITDA. He also stated that “specialty alone is clocking 27 per cent EBITDA margin,” reinforcing the emphasis on a premium mix.

CDMO pipeline expands, with a large order due in 2026

CDMO is central to the company’s medium-term narrative, both for growth and for margin stability. Jubilant Ingrevia has added more than 10 new molecules to its CDMO and Fine Chemicals portfolio. The company has indicated these are expected to contribute almost ₹1,200 crore of peak annual revenues in coming years, and has also described this as “₹1,200 crores peak annual revenue potential.”

A major US$100 million CDMO contract, covering five years, is set to commence in early 2026. Management has reiterated that it is on track to start serving the major CDMO order in early 2026, calling it a milestone expected to accelerate CDMO growth in coming quarters. The company also disclosed two major agro CDMO projects, with one starting supplies in Q1 FY26 and a second expected by January 2026.

Nutrition volumes rise, but pricing remains the constraint

Nutrition and Health Solutions is the other key pillar in the mix upgrade. The company reported strong year-on-year volume growth in vitamin B3 and choline, with record high volumes mentioned in vitamin B3 and B4. However, pricing softness weighed on reported value. Nutrition revenue declined 1% due to pricing pressures, even as volumes grew.

Management has laid out a margin path tied to mix improvement. The company expects nutrition margins to move to 16–18% as higher-value grades expand. One disclosure specifies that margins are expected to improve to 16–18% as high-value grades increase to 60–70% of the mix, particularly with higher-margin cosmetic, food, and pharma grades.

Q1 FY26 snapshot shows margin improvement despite flat revenue

In Q1 FY26, Jubilant Ingrevia reported revenue of ₹1,038 crore, described as flat. Over the same period, EBITDA rose 29% to ₹153 crore, and the EBITDA margin increased to 15% from 9% six quarters earlier. Net profit surged 54% year-on-year to ₹75 crore.

The company has linked the improvement to its “Pinnacle” strategy and to growth momentum in Specialty and Nutrition. It also pointed to a significantly expanded funnel of “100-plus new opportunities,” suggesting a broader pipeline beyond the disclosed CDMO molecules.

Capex plans: monetisation phase and a larger CDMO build-out

Jubilant Ingrevia has outlined multiple capex figures tied to its specialty pivot. It has indicated that nearly ₹2,000 crore of capex is moving closer to monetisation. Separately, a ₹2,400–2,500 crore capex program is planned for the CDMO business, to be executed in phases with an annual run-rate of around ₹600 crore.

In another disclosure, management indicated a revenue-to-capex ratio of about 1.5x, with ₹1,800 crore invested and about 50% of potential revenue already realized. It also stated that the remaining ₹1,000 crore-plus incremental revenue is expected as new capacities ramp up. The company also noted that 70% of recent ₹2,000 crore capex is targeted at Specialty and Nutrition, including new multipurpose plants for CDMO and Fine Chemicals.

Expansion roadmap: plants, R&D and acquisitions

Alongside capex, the company has listed specific initiatives aimed at expanding capability. It plans to expand the CDMO portfolio and construct a new multipurpose plant in Gajraula. It also plans to establish a Semiconductor R&D facility in Greater Noida.

In addition, the company highlighted successful dispatch from a newly constructed Agro CDMO facility and the acquisition of Remidex to accelerate the growth of its Human Nutrition business. In nutrition, management has cited demand for cosmetic-grade products and strong response to a new cGMP facility.

Targets and guidance: FY27 and FY30 milestones

Jubilant Ingrevia has set out medium and long-term targets that anchor investor expectations. It aims for ₹7,500–8,000 crore revenue and a 20% EBITDA margin by FY27, supported by ₹2,000 crore capex in specialty chemicals and the CDMO pipeline with ₹1,200 crore peak sales potential. Management has also reaffirmed a long-term target of ₹2,000 crore EBITDA by FY30.

Separately, it has referenced an additional ₹2,000–2,500 crore capex over the next 3–4 years to achieve its “Pinnacle 345 Vision,” which includes a ₹10,000 crore revenue target by FY30. Guidance was described as unchanged, with expectations of continued momentum in Specialty Chemicals and Nutrition, and partial recovery in the Acetyls portfolio.

Market impact: what investors are tracking now

The company’s disclosures place the spotlight on the quality of growth rather than only the pace of growth. Specialty Chemicals margins in the mid-20s and the stated shift to higher-margin nutrition grades underpin the expectation of higher consolidated profitability. But the company has also noted that the market is waiting for sustained proof, particularly as nutrition pricing remains soft and acetyls recovery is described as partial.

Near-term attention is likely to remain on execution milestones already disclosed: the start of supplies in agro CDMO projects (Q1 FY26 and January 2026), and the start of the major CDMO order in early 2026. Investors are also likely to track ramp-up from the capex already deployed, given management’s statement that roughly half of the revenue potential from ₹1,800 crore invested has already been realized.

Key numbers at a glance

Why the shift matters

The disclosures show a company trying to reduce dependence on commoditised chemicals and re-rate its earnings profile through specialty platforms. The pivot is visible in segment emphasis, capex allocation, and the pipeline narrative around CDMO molecules and contracted work. It is also visible in management’s statement that Specialty and Nutrition together contribute 90% of EBITDA.

The next proof points are largely operational and time-bound, and many are already on the calendar. These include the commencement of the major CDMO contract in early 2026, the phased CDMO capex program, and the ramp-up of new capacities that management expects to add ₹1,000 crore-plus incremental revenue as utilisation improves.

Conclusion

Jubilant Ingrevia is positioning Specialty Chemicals, CDMO and higher-grade nutrition as its primary growth and margin drivers, supported by large capex and an expanding molecule pipeline. Management has kept guidance unchanged and reiterated targets of ₹7,500–8,000 crore revenue and 20% EBITDA margin by FY27, and ₹2,000 crore EBITDA by FY30. The next major milestone disclosed is the start of the large CDMO order in early 2026, alongside capacity ramp-ups tied to recent investments.